Topical dutasteride 0.05% is more effective for hair growth than oral finasteride 1mg, with minimal DHT reduction. The formulation uses castor oil and MCTs for better absorption but is not widely available until 2028.
The user experienced severe side effects from finasteride, including anxiety and libido issues, and is currently using topical minoxidil and microneedling. They are considering trying dutasteride but are concerned about potential side effects.
The conversation discusses why the difference between donor and balding hair isn't studied more to find a cure for hair loss. Treatments mentioned include Minoxidil, finasteride, and RU58841.
Finasteride may be sufficient for diffuse thinning, but dutasteride is generally considered more effective, with a higher chance of hair growth. Adding oral minoxidil can improve results, though some users report side effects.
The user is not seeing success with 0.025% topical finasteride for hair loss after four months and is experiencing less side effects compared to 1mg oral finasteride. Another user suggests that it might be too soon to see results and recommends trying it for a year before making a decision.
User discusses verteporfin for hair regrowth through "super microneedling" and preventing scarring. They mention a case of an old man regrowing hair after a head injury and suggest verteporfin could recreate this result.
Kintor Pharma completed a successful Phase II clinical trial for KX-826, a treatment for androgenetic alopecia. KX-826 is similar to finasteride with minor side effects and is more backed than Cosmerna.
Clascoterone's European release is expected in Q4 2026, with FDA approval anticipated by mid-2027. The discussion includes questions about the approval timeline and potential acceleration due to unmet needs.
A 20-year-old is experiencing severe diffuse thinning and shedding despite using oral minoxidil for 12 months and dutasteride for 8 months, after previously trying finasteride. They are frustrated with the lack of improvement and considering trying RU58841.
The conversation is about whether taking 0.5mg of finasteride daily is as effective as 1mg for hair regrowth and if there are long-term studies supporting the lower dose. The user is considering the lower dose to save money and reduce concerns about side effects.
A user reported significant hair growth improvements using 1mg finasteride and 2.5mg minoxidil daily, despite minor side effects. The doctor advised against combining multiple treatments to identify what works.
A 16 year old's experience with using pyrilutamide to treat hair loss, and the potential side effects of adding tretinoin to minoxidil and finasteride treatments.
The user is experiencing low libido and mood swings after starting a low dose of topical finasteride. They are considering further blood tests to investigate low testosterone levels and other hormonal factors.
GT20029 and pyrilutamide are both androgen antagonists but work differently; GT20029 degrades the androgen receptor, while pyrilutamide blocks DHT from binding. GT20029 is expected to have similar efficacy to CosmeRNA.
Androgenic alopecia (AGA) might have evolved to reduce prostate cancer risk by increasing UV exposure to the scalp, but this theory is debated. Treatments like minoxidil and finasteride are used for AGA, though the exact causes and evolutionary reasons for hair loss are unclear.
Topical finasteride is believed to reduce scalp DHT more than oral forms, but its effectiveness is questioned due to inconsistent application and absorption. Oral finasteride is considered more effective because it consistently reduces systemic DHT, ensuring more reliable results.
The user has been using minoxidil, finasteride, a laser cap, and ketoconazole shampoo for hair loss without success and is seeking advice on further tests or treatments. They have a family history of hair loss and have not yet undergone dermatologist or trichology tests.
The conversation is about gathering serum DHT data from individuals taking dutasteride to investigate its efficacy, especially in cases with unexpectedly low DHT reduction. The aim is to explore potential genetic factors affecting drug metabolism.
The user is using dutasteride and minoxidil for hair loss and noticed new hair growth after initially thinking there was no progress. Encouragement was given to continue the treatment as it takes time to see full results.
PP405 is a potential hair loss treatment that may activate dormant hair follicles, but there are concerns about its effectiveness, cost, and side effects. Users discuss treatments like minoxidil, finasteride, and RU58841, expressing skepticism about PP405's long-term success and accessibility.
Clascoterone 5% and PP405 are being discussed as potential future treatments for hair loss, with clascoterone nearing phase three completion and PP405 possibly taking a cosmetic route to market. Current treatments like minoxidil, finasteride, and RU58841 are mentioned as effective in slowing hair loss, but a complete cure remains elusive.
The user has been using 0.5mg finasteride every other day and applying minoxidil twice daily for three months but hasn't noticed any hair growth or increased thickness yet. They are questioning if they should expect progress at this stage.
Users discussed using lower doses of finasteride and minoxidil for hair loss. Some experienced side effects like arrhythmia, while others reported slowed hair thinning but not complete prevention.
Amplifica is testing a compound called AMP-303 for hair loss, but it's not Scube3 or osteopontin. The timing for the results from the clinical trial is unknown.
The user experienced hair regrowth with dutasteride but later lost progress despite using minoxidil foam and dermastamping. Suggestions included reducing dermastamping frequency, conducting blood tests, and considering oral minoxidil or different brands of dutasteride.
Dutasteride is more effective in gel capsule form due to better absorption, as it is fat-soluble. If only pills are available, taking them with fat or increasing the dose slightly may help.
The conversation is about the ineffectiveness of 1% ketoconazole for hair loss, with the user stating that studies support the 2% version and even that has minimal results. The user also mentions using minoxidil, which dries out their scalp, and ketoconazole worsens it.
The conversation is about a person experiencing treatment-resistant androgenic alopecia despite using high doses of dutasteride and minoxidil, along with other treatments like microneedling and purilutamide. Suggestions include considering a hair transplant, checking medication authenticity, and exploring other treatments like RU58841 or topical estradiol.